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Introduction
Cell migration is central to development and post-traumatic
regeneration. Tuning of the pericellular environment is
required to achieve optimum adhesiveness for the mobile
phenotype. The increased chondroitin sulphate proteoglycans
(CSPGs) reported in injured neural environments of adult
mammals (Braunewell et al., 1995; Shum and Chau, 1996;
Sandvig et al., 2004; Silver and Miller, 2004) suggest
contribution to this effect. This is reinforced by in vitro studies
which demonstrated expression of pericellular CSPGs as a
requirement for invasive migration into a fibrin matrix (Henke
et al., 1996; Clarke et al., 2004). The multiplicity of core
proteins of CSPGs and the heterogeneity of chondroitin
sulphate substitutions to the core have confounded attempts to
distinguish forms that facilitate cell migration in vivo. The
distinctive increases in 6-sulphated chondroitins during axonal
regrowth in crushed sciatic nerves (Chau and Shum, 1997; Liu
et al., 2001) and in brain development (Fernaud-Espinosa et
al., 1996; Kitagawa et al., 1997; Properzi et al., 2005) however
highlight 6-sulphation of chondroitins as a key step that the
migrant cell exploits to tune its pericellular environment.
The sulphation of chondroitins is catalyzed by chondroitin
6-sulphotransferase (C6ST), chondroitin 4-sulphotransferase
and uronyl 2-sulphotransferase (Habuchi, 2000; Fukuda et al.,
2001). Differential sulphation is thought to depend on correct
juxtaposition of the relevant sulphotransferase(s) and the
acceptor chondroitin domain within a subcompartment of the
Golgi network (Prydz and Dalen, 2000; Silbert and
Sugumaran, 2002). In animals that develop normally, there is
little reason to suggest defects of these proteins or their
colocalisation in time and space. The distinctive increase in 6-
O-sulphated isomers of chondroitin sulphate in the injured
environment (Chau and Shum, 1997) could therefore be a
consequence of stimulated expression of the C6ST gene.
Molecular cloning of human C6ST revealed two orthologous
genes, C6ST-1 (Fukuta et al., 1995; Fukuta et al., 1998;
Uchimura et al., 1998) and C6ST-2 (Kitagawa et al., 2000).
Expression of both isoforms in the brain was evident during
development but negligible in the adult. Attempts to pursue
functional analysis in vivo with mice deficient in the C6st1
gene found no apparent abnormality in brain development
(Uchimura et al., 2002), suggesting possible redundancy
among the C6ST isoforms. By contrast, glial cells in the
lesioned rat brain were found to upregulate C6st1 expression
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traumatic regeneration. The differential increase in 6-
sulphated chondroitins during axonal growth in both
crushed sciatic nerves and brain development suggests that
chondroitin 6-sulphotransferase-1 (C6ST-1) is a key
enzyme that mediates cell migration in the process. We
have cloned the cDNA of the C6ST-1 gene (C6st1)
(GenBank accession number AF178689) from crushed
sciatic nerves of adult rats and produced ribonucleotide
probes accordingly to track signs of 6-sulphated
chondroitins at the site of injury. We found C6st1 mRNA
expression in Schwann cells emigrating from explants of
both sciatic nerve segments and embryonic dorsal root
ganglia. Immunocytochemistry indicated pericellular 6-
sulphated chondroitin products around C6ST-1-expressing
frontier cells. Motility analysis of frontier cells in cultures
subjected to staged treatment with chondroitinase ABC
indicated that freshly produced 6-sulphated chondroitin
moieties facilitated Schwann cell motility, unlike
restrictions resulting from proteoglycan interaction with
matrix components. Sciatic nerve crush provided further
evidence of in vivo upregulation of the C6ST-1 gene in
mobile Schwann cells that guided axonal regrowth 1-14
days post crush; downregulation then accompanied
declining mobility of Schwann cells as they engaged in the
myelination of re-growing axons. These findings are the
first to identify upregulated C6st1 gene expression
correlating with the motility of Schwann cells that guide
growing axons through both developmental and injured
environments.
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(Properzi et al., 2005). Studies with cell cultures found that
matrix-bound proteoglycans bearing 2,6- or 4,6-bissulphated
chondroitin sulphate disaccharide repeats possessed neurite-
outgrowth-promoting properties by virtue of their affinity for
such factors as fibroblast growth factors, pleiotrophin and
midkine (Clement et al., 1998; Deepa et al., 2002). Growth
factors that are bound to CSPGs could be competed out by 6-
sulphated chondroitins but not by 4-sulphated chondroitins.
Variations in sulphation of chondroitin sulphate glycoforms
can therefore fine-tune bio-availability of growth factors to
sprouting neurites.
For Schwann cells to support axonal regrowth, they assume
a mobile phenotype to catch up with regenerating sprouts that
emerge and extend within hours from the nodes of Ranvier
proximal to the site of injury (Torigoe et al., 1996; Tseng et
al., 2003). Direct evidence of Schwann cell migration along
axons in vivo has recently been shown against the transparency
of zebrafish embryos and ErbB signaling was suggested as a
requirement for directed migration of the cells (Lyons et al.,
2005). Motile machinery and directive signaling aside, we
hypothesise that migrating Schwann cells upregulate
expression of C6ST genes to produce pericellular 6-sulphated
chondroitin moieties that function in counteracting cell
adhesiveness of the substrate. We exploited explants of
embryonic dorsal root ganglia (DRG) to study both leading and
lagging Schwann cells in relation to developing neurites in
vitro. C6st1 expression was identifiable in leading Schwann
cells that made frequent and transient contacts with developing
neurites; this contrasted with the undetectable expression in
lagging Schwann cells that remained associated with axon
fascicles. We also used sciatic nerve crush to provide a
regenerative environment for the study of mobile Schwann
cells in relation to regrowing axons in vivo. C6st1 expression
was upregulated in Schwann cells that became mobile at early
stages post crush, ahead of regrowing axons. Schwann cells
that resumed the myelinating phenotype downregulated C6st1
expression. Our results are the first to suggest that 6-sulphated
chondroitin moieties are produced to facilitate Schwann cell
migration during axonal growth.
Results
Rat C6st1 shows sequence homology to the mouse and
human gene
Following the discovery of increased water-soluble 6-
sulphated chondroitin isoforms in the crushed sciatic nerve,
we recovered RNA from crushed nerves and used it to identify
and clone the cDNA of rat C6st1 (Fig. 1A). From the
nucleotide sequence of the cloned cDNA, the amino acid
sequence of the protein was deduced (supplementary material
Fig. S1A). The hydropathy plot reveals a hydrophobic stretch
of 19 residues towards the N-terminus (supplementary
material Fig. S1B), predicting a type II transmembrane
domain that is common to many Golgi-associated
sulphotransferases and glycosyltransferases. In addition, the
six N-linked glycosylation sites predicted in the rat sequence
(supplementary material Fig. S1A) correspond to those found
in the mouse and human sequences.
The amino acid sequence of the rat C6ST-1 indicated 87, 93
and 74% identity to the reported sequences of the human,
mouse, and chick C6ST-1, respectively (supplementary
material Fig. S1C). Within the regions of conserved amino
acids, motifs for the binding of 5-phosphosulphate and the 3-
phosphate components (supplementary material Fig. S1C) of
the activated sulphate donor, PAPS, could be located.
Sulphation of chondroitin by the recombinant rat C6ST-1
To confirm that the rat cDNA encodes a protein with C6ST
activity, the sequence was expressed in COS-7 cells. We
generated two different expression constructs, pcDNA-C6ST-
1 containing the full-length C6st1, and pcDNA-His-C6ST-1
lacking the N-terminal transmembrane domain but retaining
the PAPS-binding sites and the catalytic domain. When
Journal of Cell Science 119 (5)
Fig. 1. Recombinant rat C6ST-1 catalyzes sulphation of chondroitin
at C-6 of GalNAc residues. (A-C) The sulphotransferase reaction
was carried out with chondroitin as the acceptor substrate under
conditions described in the Materials and Methods with constructs
containing C6ST (A), His-C6ST (B) and His-LacZ (C). The 35S-
labelled product was digested with chondroitinase ACII () or
chondroitinase ACII + chondro-6-O-sulphatase (*). The digests were
subjected to Partisil-10 SAX HPLC and eluted fractions were
monitored for radioactivity. Arrows indicate elution positions of
standard disaccharides: (1) 2-acetamide-2-deoxy-3-O-(-D-gluco-4-
enepyranosyluronic acid)-D-galactose (Di-0S); (2) 2-acetamide-2-
deoxy-3-O-(-D-gluco-4-enepyranosyluronic acid)-6-O-sulpho-D-
galactose (Di-6S); (3) 2-acetamide-2-deoxy-3-O-(-D-gluco-4-
enepyranosyluronic acid)-4-O-sulpho-D-galactose (Di-4S); (4)
inorganic sulphate; and (5) 2-acetamide-2-deoxy-3-O-(-D-gluco-4-
enepyranosyluronic acid)-4,6-bis-O-sulpho-D-galactose (Di-diSE).
The broken line depicts the eluting salt gradient.
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935C6ST and migration of Schwann cells
transfected into COS-7 cells, both constructs yielded products
that indicated similar sulphotransferase activity in an in vitro
assay with chondroitin as acceptor. The activities were at least
20-fold greater than that of control transfectants bearing
pcDNA-His-LacZ (Table 1). This confirmed that the expressed
product of the cloned cDNA possessed sulphotransferase
activity.
To determine whether the sulphotransferase assay succeeded
in the transfer of sulphate from PAP[35S] to C-6 of GalNAc
residues of chondroitin, the 35S-labelled products were
digested with chondroitinase ACII to yield disaccharides that
were then analyzed with the use of Partisil-10 SAX HPLC (Fig.
1). A single 35S-labelled peak (peak 2 in Fig. 1A,B) that
corresponded to reference Di-6S was observed. Further
digestion of the labelled disaccharide with chondro-6-
sulphatase resulted in a shift of the radioactive peak to an
elution position that corresponded to inorganic [35S]sulphate.
This was observed in both test transfectants that carried either
pcDNA-C6ST-1 (Fig. 1A) or pcDNA-His-C6ST-1 (Fig. 1B)
but not in control transfectants that carried pcDNA-His-LacZ
(Fig. 1C). These results confirmed that C6ST-1 catalyzed the
transfer of sulphate only to C-6 of GalNAc residues of
repeating disaccharide units of chondroitin.
Upregulated C6st1 mRNA in Schwann cells that
emigrate from sciatic nerve explants
To study C6st1-expressing cells derived from the nerve away
from hematogenous infiltrates and axonal sprouts, we cultured
explants of adult rat sciatic nerve segments where severed
axons had degenerated and compared these with confluent
cultures of purified Schwann cells. Schwann cells that migrated
out of the sciatic nerve explants showed intense CS56
immunopositivity (Fig. 2A), contrasting with the barely visible
CS56 immunopositivity of Schwann cells in confluent cultures
(Fig. 2B). This suggests that CSPGs are produced in
association with Schwann cell emigration from the nerve
explants and that the chondroitin moieties are enriched in
tetrasaccharide motifs (Ito et al., 2005) of 4-sulphated
disaccharide linked to 2,6-bissulphated disaccharide as
recognised by the monoclonal antibody CS56. The proportion
of Schwann cells expressing the C6st1 transcript was also
significantly higher among those exiting from sciatic nerve
explants than those in confluent cultures (41.1±5.2% versus
7.1±2.9%, P<0.001; Fig. 2C). Taken together, the results
indicate that under in vitro conditions that allow migration of
cells out of explants, migratory Schwann cells upregulate
C6st1 expression and that these cells produce chondroitin
moieties bearing CS56 epitopes.
Table 1. Overexpression of C6st1 in COS-7 cells
Sulphotransferase activity 
Plasmid (pmol/hour/mg protein)
(i) pcDNA-C6ST-1 13.36±1.23
(ii) pcDNA-His-C6ST-1 12.53±0.91
(iii) pcDNA-His-LacZ 0.58±0.12
COS 7 cells were transfected with an expression plasmid containing either
(i) the complete coding sequence of C6ST-1 (pcDNA-C6ST-1), (ii) a
truncated C6ST-1 sequence fused to the sequence that encodes (His)6
(pcDNA-His-C6ST-1), or (iii) the pcDNA vector alone. Cell homogenates
were assessed for sulphotransferase activity with the use of PAP[35S] as donor
and chondroitin as acceptor; the yield of Di-6[35S] after digestion of the
product with chondroitinase ACII was determined. Values represent mean ±
s.d. of triplicate cultures.
Fig. 2. C6st1 mRNA expression is upregulated in Schwann cells
emigrating from sciatic nerve explants but not in Schwann cells at
confluence. Schwann cells emigrating from explants of sciatic nerves
(adult rats) are compared with confluent cultures of purified Schwann
cells. (A) Phase-contrast (A1) and immunofluorescence (A2) views of
emigrating Schwann cells doubly immunopositive for the S100 and
CS56 epitopes. Emigrating Schwann cells reveal colocalisation of
fluorescence in situ hybridisation signal for C6st1 mRNA (C6ST) and
immunofluorescence for either S100 (A3) or GFAP (A4). The GFAP-
positive migrating Schwann cells show negligible hybridisation
signal when tested with the sense riboprobe (A5). (B) Phase-contrast
(B1) and combined hybridisation- and immunofluorescence (B2)
views of confluent cultures of purified Schwann cells, showing
insignificant expression of C6st1 mRNA in spindle-shaped, bipolar,
S100-positive Schwann cells. Similarly, these Schwann cells were
S100-positive but CS56-negative, as observed with double
immunofluorescence (B3). (C) Histogram showing prevalence of
C6ST-expressing, S100-positive Schwann cells (SC) in the sciatic
nerve (SN) explant over those in confluent cultures of purified
Schwann cells (P<0.001). Total Schwann cell counts are listed under
the histogram. Error bars represent s.e.m. of three independent
experiments. Bars, 25 m (B, upper panels in A); 50 m (lower
panels in A).
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Downregulated C6st1 mRNA in Schwann cells that
engage in interactions with axon networks 
To find if migrating Schwann cells modulate C6st1 expression
in the presence of growing axons, DRG explants of E15 rats
were studied in culture. We found expression of C6st1
transcripts in Schwann cells that populated the migration front,
sometimes ahead of axonal arbors (Fig. 3B). Time-lapse video
microscopy revealed frequent changes in shape and mobility
ranges of up to 2 m/minute among Schwann cells at the
frontier (950-1400 m from the DRG centre). They frequently
but transiently contacted axonal arbors and changed axonal
contacts along the way (supplementary material Movie 1 and
Fig. S2). Occasionally, the Schwann cells made strides of 2
m/minute with lamellipodial extensions in the forward
direction followed by tail retraction. Expression reached barely
detectable levels among Schwann cells that lagged behind and
became engaged with axonal fascicles (Fig. 3A-C;
supplementary material Fig. S2). Evidence is thus provided not
only for the expression of C6st1 in migrating Schwann cells
but also for downregulated expression in Schwann cells that
became limited in mobility and committed to interactions with
axons. 
Changes in Schwann cell motility with chondroitinase
ABC treatment of DRG cultures
If C6ST-expressing Schwann cells at the frontier were
secreting 6-sulphated chondroitin products to modulate
motility, we proposed that digestive removal of these moieties
would affect Schwann cell motility. To test this, DRG cultures
were pre-treated for an extended period (40 hours) with
chondroitinase ABC. Enzyme-treated cultures revealed 3B3
immunopositivity about S100-positive Schwann cells at the
migration front (Fig. 4A-D), whereas control treatment showed
no 3B3 immunoreactivity (Fig. 4E-H). The stubs of 6-
sulphated disaccharides of chondroitin, detectable by 3B3
immunoreactivity (Caterson et al., 1984), provide not only
evidence for the action of chondroitinase ABC on CSPGs, but
also proof of the concept that proteoglycans bearing 6-
sulphated chondroitin moieties were secreted into the
pericellular environment of Schwann cells at the frontier.
Parallel cultures were studied with time-lapse video
microscopy. Motility analysis of Schwann cells revealed a
general shift to wide-range motilities of 0-4.6 m/minute
following chondroitinase ABC treatment (compare Figs S2 and
S3 in supplementary material). This suggests that the majority
of chondroitin sulphate moieties pre-existing in the
environment of the DRG explant cultures limited Schwann cell
motility. This does not necessarily reflect the property of
chondroitin sulphate moieties freshly produced by migrating
Schwann cells. To demonstrate effects of chondroitin sulphate
moieties freshly produced by Schwann cells actively migrating
in the frontier, cultures were pre-digested of existing matrix
chondroitin sulphate (16 hours) with chondroitinase ABC.
Cultures were then paired, one with enzyme treatment during
3 hours of time-lapse video recording versus another with
omission of enzyme in control treatment for the same period,
for the comparison of Schwann cell motility. Results of these
experiments indicated that Schwann cells at the frontier tended
to decline in motility with the 3-hour enzyme treatment: a
decrease from 30% to 16% of mapped Schwann cells falling
within the high-motility range (50% of steps exceeding
2.3 m/minute; Fig. 4I) and an increase from 20% to 43% of
mapped Schwann cells falling within the low-motility range
(50% of steps lower than 1.5 m/minute, Fig. 4I). In situ
hybridisation for C6st1 mRNA in cultures fixed after the live-
cell imaging confirmed expression among the Schwann cells
Journal of Cell Science 119 (5)
Fig. 3. C6st1 mRNA expression is upregulated in migrating Schwann
cells and not in Schwann cells that are engaged with axonal fascicles.
DRG explants (E14 rats) were cultured on laminin-coated coverslips
for 2 days in 10% FBS-DMEM-F12 supplemented with NGF (20
ng/ml). (A) Left panel, phase-contrast view of axons (small arrows)
and cells radiating from the explant. Right panel, the same view
showing C6st1 mRNA (C6ST) hybridisation signals in cells at the
frontier (box); the enlarged inset image of the boxed region reveals
the various morphologies of C6st1-expressing cells. (B) In situ
hybridisation for C6st1 mRNA combined with SMI31
immunocytochemistry for axons. Left panel, SMI31-positive fibres
(small arrows) radiate as networks and fascicles from a DRG explant.
C6st1 hybridisation signals were hardly visible in cells associated
with axonal fascicles. Towards the frontier (1090 m from DRG
centre), C6st1-expressing were visible. Right panel, an enlarged view
of the frontier zone shows scattered C6st1-expressing cells
(arrowheads) apparently in advance of SMI31-positive axons (small
arrows). (C) Double immunofluorescence for SMI31-positive axons
and S100-positive Schwann cells. S100-positive cells can be seen
crowded around the DRG explant (upper right), aligned as chains
along SMI31-positive axon fascicles (small arrows), and as scattered
cells (arrowheads) in the frontier. The large arrow in each panel
indicates the direction of projection of growing axons and emigrating
cells from the DRG centre. Bars, 200 m (A,B), 100 m (C).
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937C6ST and migration of Schwann cells
mapped for motility assessment (Fig. 4J,K). Given the inherent
heterogeneity in sulphation of the chondroitins, the results
suggest that chondroitin moieties produced by C6st1-
expressing Schwann cells at the frontier of the 3-hour live-cell
observation are sufficient to facilitate migration of Schwann
cells at the frontier.
Upregulated C6st1 mRNA in GFAP-positive Schwann
cells in an early phase of tissue reorganisation after
nerve crush
To examine whether the mobile Schwann cells in vivo also
upregulate C6st1 expression, sections of the sciatic nerves at
indicated stages after injury were hybridised with the anti-
sense riboprobe for C6st1. Progressively intensifying signals
were observed in the cytoplasm of Schwann cells that initially
took the form of annulae around as yet undetectable myelin
within 1 day post crush (dpc) (Fig. 5A) and expanded to
various shapes that filled the Bands of Büngner by 3-7 dpc
(Fig. 5A). During this time, the injured axons degenerated
distal to the injury and Schwann cells were mobile to
scavenge myelin and axonal debris. By 14 dpc, the signals
condensed and returned to the annular morphology about
regrowing axons (Fig. 5A). Day 28 post crush nerves
indicated barely detectable C6st1 expression, similar to that
observed in normal nerves (Fig. 5A). The hybridisation
patterns revealed with the antisense riboprobe were clearly
different from those revealed with the sense riboprobe, as
exemplified by the section of 14 dpc sciatic nerves (Fig. 5A).
The results support a wave of upregulated C6st1 expression
in association with Schwann tube reorganisation after crush
injury.
To provide further evidence that upregulated C6st1
expression was indeed in a mobile subset of Schwann cells,
sections of 7 dpc sciatic nerves were subjected to in situ
hybridisation for C6st1 mRNA and further immunostained for
markers of Schwann cells, S100 (expressed in both non-
myelinating and myelinating Schwann cells) or GFAP
(expressed in non-myelinating Schwann cells and reversibly
suppressed in myelinating Schwann cells) (Jessen et al., 1990;
Jessen and Mirsky, 2005) (Fig. 6). The merged images
indicated that not all S100-positive cells expressed C6st1
mRNA (Fig. 6C,G) but all C6st1-expressing cells showed
GFAP immunopositivity (Fig. 6K,O). The results indicate that
a sub-population of Schwann cells that reacted to the injury
with GFAP expression upregulated synthesis of C6ST-1.
Although ED-1-positive macrophages recruited to the injured
site were identifiable in the tissue sections, only a few of the
ED-1-positive cells indicated C6st1 mRNA expression.
Perivascular, epineurial and perineurial fibroblasts indicated
expression of C6st1 mRNA similar to those in uninjured
tissues. Expression of C6st1 was therefore upregulated mainly
in the sub-population of Schwann cells that reacted to the
injury with GFAP expression.
Alternative evidence of early C6st1 mRNA expression in the
crushed sciatic nerve was obtained from RT-PCR analysis that
targeted a 675 bp fragment of the  rat C6st1 (427-1101 bp,
GenBank AF178689). Signals of the target C6ST-1 sequence
relative to that of the reference GAPDH were increased as early
Fig. 4. Chondroitinase digestion of
pericellular proteoglycans of migrating
Schwann cells at the DRG frontier
results in a shift to lower mobilities.
(A-D) Extended treatment with
chondroitinase ABC (40 hours)
revealed cells radiating from the DRG
centre (towards lower right, phase-
contrast view in A), many of which
were S100-positive Schwann cells (B)
bearing pericellular 3B3-
immunopositivity (C). (D) Merged
image of B and C. (E-H) Although
control treatment with the heat-
inactivated enzyme similarly revealed
cells radiating from the DRG centre
(towards mid-right, phase-contrast
view in E), none of the S100-positive
cells (F) showed pericellular 3B3-
immunopositivity (G). (H) Merged
image of F and G. The bar chart (I)
shows the shift towards lower mobility
among Schwann cells at the migration
front during time-lapse video recording
of cultures undergoing a further 3-hour
treatment with (+) chondroitinase ABC
compared with those without (–) the
enzyme. Mobility ranges are classified
high at >2.3 m/minute, intermediate
at 1.5-2.3 m/minute and low at <1.5 m/minute. Results are the mean ± s.e.m. of triplicate DRG experiments prepared for time-lapse video
recording (*P=0.46; **P=0.29). (J,K) One of these DRGs is shown both under light microscopy to reveal C6st1 mRNA signals (J) and under
phase-contrast optics to reveal cell profiles (K). Cells that had been mapped for mobility measurements were numbered as indicated. The
corresponding video clip and profile of cell mobility are shown in supplementary material Movie 2 and Fig. S3. Bars, 100 m (A-H) and (J,K).
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Fig. 5. Upregulated C6st1 mRNA in
Schwann cells during an early phase of
tissue reorganisation after nerve crush.
(A) In situ hybridisation patterns of
C6st1 mRNA revealed with DIG-labelled
antisense probes on transverse
cryosections of normal and post-crush
sciatic nerves (at 1, 3, 7, 14 and 28 days
as indicated). Arrows in the zoom views
(insets) indicate significant C6st1
transcripts in cells circumferential to
axons (1 dpc), in irregularly shaped cells
profusely distributed about Schwann
tubes undergoing reorganisation (3 dpc
and 7 dpc). By 14 days post crush,
signals were detectable only in the small-
diameter Schwann tubes. Signals
approach the normal pattern by 28 dpc.
Occasional C6st1 transcripts are
detectable around blood vessels
(arrowheads in normal and 28-day
images). The DIG-labelled sense probe
yielded negligible hybridisation signal
against the background as exemplified
with a section of a 14 dpc sciatic nerve.
(B) RT-PCR analysis of C6st1 mRNA
expression for the profile of change in
post-crush sciatic nerves (days 1-28 as
indicated) against the expression of GAPDH as an internal reference. Gel bands are shown directly above the corresponding histogram of
C6ST: GAPDH intensity ratio. Results are the mean ± s.e.m. of three independent sets of analyses. Bars, 200 m.
Fig. 6. Expression of C6st1 mRNA in Schwann
cells in 7 dpc nerves. Fluorescence in situ
hybridisation for C6st1 mRNA in combination
with fluorescence immunohistochemistry for
either S100 (A-H) or GFAP (I-P). Images
represent both transverse (A-D and I-L) and
longitudinal (E-H and M-P) cryosections of 7
dpc sciatic nerves at the crush site. Phase-
contrast views of the tissues are shown in the
right-hand column. Merges of
immunocytochemistry and hybridisation images
are shown (C,G,K and O) with enlarged views
(insets) of the boxed areas (C and K). Only some
of the S100-positive Schwann cells expressed
the C6st1 transcript (arrows) but all C6st1-
expressing Schwann cells were GFAP-positive.
Bars, 100 m (A-P); 50 m (insets).
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939C6ST and migration of Schwann cells
as 1 dpc and remained high up to 14 dpc. This contrasts with
ratios indicated by nerves at 28 dpc or normal nerves (Fig. 5B)
in which Schwann cell motility is expected to be low. The
results support the notion of upregulated C6st1 expression in
an early phase of tissue reorganisation after sciatic nerve crush.
Discussion
In this first report of C6st1 expression in migratory Schwann
cells, we followed up the evidence of increased 6-sulphated
chondroitins in crushed sciatic nerves and cloned the cDNA of
the rat C6st1. With riboprobes generated against the rat C6st1
sequence, we found upregulated expression in Schwann cells
that assumed migratory phenotypes during an early phase of
tissue reorganisation after sciatic nerve crush. Expression
returned to basal levels when Schwann cells resumed
association with axons as in the myelinating phenotype. In
cultures of sciatic nerve segments where severed axons have
degenerated, C6st1 expression among migrating Schwann cells
was independent of axons. To observe Schwann cells and
growing axons in action, we successfully used cultures of
embryonic DRG and staged treatment of the cultures with
chondroitinase ABC to provide new insight to the dynamics of
C6st1-expressing Schwann cells at the migration front where
they make transient contacts with axonal arbors along the way.
This contrasts with undetectable C6st1 expression among
Schwann cells that remain persistently with axonal fascicles.
Although increased chondroitin sulphates have been
reported in injured peripheral nerves (Shum and Chau, 1996;
Zuo et al., 1998), the fact that these are mainly soluble and
extracellular has left the cellular source of the various
sulphated chondroitin isoforms unclear. Attempts to target the
core proteins of CSPGs found immunopositivities associated
with non-neuronal elements of peripheral nerves – Schwann
cells, perineurial and endoneurial fibroblasts, and blood vessels
(Braunewell et al., 1995; Martin et al., 2001; Schneider et al.,
2001; Rezajooi et al., 2004), but these at best indicated where
the secreted or shed CSPGs were deposited. Little is known
about the sulphated glycoforms on site or at source. In the
injured sciatic nerve, biochemical analyses revealed a
distinctive increase in 6-sulphated chondroitin isoforms
(Braunewell et al., 1995; Chau and Shum, 1997). This change
followed a time course coincident with tissue reorganisation
towards nerve regeneration. This led us to find C6st1
expression in migratory cells and to determine whether
expression persists when the migratory cells associate with
regrowing axons.
In this study, we found upregulated expression of C6st1
mRNA in an early phase of tissue re-organisation after nerve
injury. Although C6st1 signals were identifiable in
perivascular, perineurial and endoneurial fibroblasts of crushed
nerves, expression in these cell types did not differ significantly
from those in uninjured sciatic nerves. By contrast, a
significant increase in C6st1 signals was found in Schwann
cells that changed from quiescent, myelinating cells in the
uninjured nerve into various forms in the reorganising
Schwann tubes of the crushed sciatic nerve. One early reaction
of myelinating Schwann cells to the loss of contact with axons
involves transformation to myelin-phagocytosing cells (Hirata
et al., 2000). Another possibly related immediate response
involves the release of galectin-1 from damaged axons and
Schwann cells (Fukuya et al., 2003). Injury-induced production
of nitric oxide into the extracellular environment mediates
conversion of galectin-1 to the oxidised form (Levy et al.,
2000). Given that oxidised galectin-1 stimulated peritoneal
macrophages to produce soluble factors that promoted
Schwann cell migration in vitro (Horie et al., 2004), injury-
induced activation of resident, endoneurial macrophages in
vivo (Mueller et al., 2001) could likewise facilitate the
conversion of myelinating Schwann cells to a mobile
phenotype that scavenges myelin debris. In the present study,
we further found GFAP-positive Schwann cells upregulated in
C6st1 expression in the crushed nerve. GFAP expression is
characteristic of both immature and non-myelinating Schwann
cells (Jessen et al., 1990; Jessen and Mirsky, 2005) and is
recapitulated as early as 24 hours after nerve injury (Cheng and
Zochodne, 2002). Given an association of GFAP expression
with Schwann cell motility, we suggest that enzymatic activity
of the upregulated C6st1 yields 6-sulphated chondroitin
products that modulate adhesion of Schwann cells to the basal
lamina in coordination with the increased cell motility.
Our in vitro observations reinforce this suggestion. With
cultures of sciatic nerve segments, migrating Schwann cells
removed from axonal influence were clearly distinguishable by
expression of GFAP and C6st1. With cultures of embryonic
DRG explants treated in stages with chondroitinase ABC, we
were able to decipher facilitatory effects of chondroitin
sulphate moieties on the motility of Schwann cells at the
migration front during 3 hours of time-lapse video recording.
Not only were these Schwann cells distinguishable by C6st1
mRNA expression, products of the C6ST activity were
identifiable as 3B3-immunopositivity in their pericellular
environment. These Schwann cells apparently sustained axonal
growth through frequent neurotrophic contacts with
arborisations at the frontier. The shape changes of these
Schwann cells also suggest dynamic renewal of pericellular 6-
sulphated chondroitin moieties. Given that the 6-sulphated
chondroitin moieties have not entered states of aggregation
characteristic of those in the extracellular matrix, there is
implication for their involvement in transient destabilisation of
cell adhesion to the substratum or in trophic interactions with
axonal arbors.
As Schwann cells migrate ahead, we expect a trail of CSPG
deposits that represent various states of aggregation with
matrix molecules. Both electron microscopy and computer
modelling of chondroitin sulphate isomers have shown that 6-
sulphated chains assume a secondary structure that can
electrostatically and sterically accommodate close packing of
6-sulphated and non-sulphated chondroitins but not 4-
sulphated chondroitins (Scott et al., 1992). The capacity for
aggregation among 6-sulphated chondroitins and non-
sulphated glycosaminoglycans such as hyaluronans (Turley
and Roth, 1980; Scott, 2003) suggests a matrix that is not
readily penetrable by advancing terminals of growing axons.
Neuritic outgrowths that do pioneer through a matrix
dominated by aggregating glycosaminoglycans and
proteoglycans will necessarily provide the scaffold to which
follower outgrowths can fasciculate. Fasciculation has indeed
been shown in the guidance of axons through an environment
of aggregating CSPGs (Snow et al., 2003). In DRG explants,
we also observed fasciculated neurites in regions where neurite
outgrowth navigated through a matrix deposited by C6st1-
expressing, migratory Schwann cells.
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In addition to C6st1-expressing Schwann cells that
emigrated free from each other, we found low-to-negligible
C6st1 expression among Schwann cells that were committed
to engagement with axonal fascicles as evident in cultures of
embryonic DRG explants. This latter is consistent with the low
chondroitin sulphate expression that we found in confluent
cultures of purified Schwann cells. These Schwann cells turned
out to participate in axon ensheathment and myelination in
nerve-bridging channels that guide axonal regrowth across
injured nerve stumps, not only in the sciatic nerve but also in
the spinal cord (Chau et al., 1999; Chau et al., 2004; Bunge,
2001). The pericellular environment of low C6st1-expressing
Schwann cells are therefore amenable to sustained cellular
contact and Schwann cell-guided axonal growth.
Overall, these observations reveal 6-sulphation of
chondroitins as a mechanism to fine-tune the pericellular
environment of Schwann cells both in the developmental
programme of the embryonic DRG and in the regenerative
programme of the crushed nerve. In both programmes, GFAP-
positive Schwann cells are the major cellular source of
upregulated C6st1 that contributes to the production of
pericellular 6-sulphated CSPGs. The expression is upregulated
in coordination with Schwann cell migration and becomes
downregulated when Schwann cells are engaged in interactions
with axonal fascicles. Increased 6-sulphated chondroitin
domains in the pericellular environment of Schwann cells
provide optimum adhesiveness for the mobile phenotype of
Schwann cells. Further work will be necessary to understand
how the pioneer axons succeed to negotiate through chondroitin
sulphate-enriched matrix deposits at different stages.
Materials and Methods
Rats, explants, and Schwann cell culture
Nerve crush was performed on sciatic nerves of pentobarbital-anaesthetised (40
mg/kg body weight) male Sprague Dawley rats (200-250 g) as described (Shum and
Chau, 1996). After 1, 3, 7, 14 and 28 days of recovery, animals were sacrificed by
decapitation and the sciatic nerves were collected. Sciatic nerves were also collected
from uninjured animals as controls. All procedures were in strict accordance with
the NIH Guide for the care and use of laboratory animal and approved by the
Committee on Use of Live Animals for Teaching and Research, Faculty of
Medicine, The University of Hong Kong.
In some cases, sciatic nerves were harvested from uninjured rats for the
preparation of Schwann cell cultures (Morrissey et al., 1991). Briefly, nerves were
stripped of connective tissue, cut into 1-mm segments, and cultured in 10% FBS-
DMEM. When emigrating cells reached confluence, explant tissues were
subcultured. The process was repeated four to six times until 99% of cells that
emigrated from the explants were Schwann cells. The explants were dissociated
with 0.5% collagenase (Sigma, St Louis, MO) in 15% FBS-DMEM (24 hours,
37°C) and then seeded onto poly-L-lysine-coated flasks. Cell proliferation was
stimulated by repeated treatment with forskolin (20 M; Sigma) and pituitary
extract (20 g/ml; Sigma). Cells were then returned to 10% FBS-DMEM and
cultured for 7 days before they were subcultured onto poly-L-lysine-coated
coverslips.
Dorsal root ganglia were dissected from E15 rats in serum-free medium. Two to
three explants were seeded per laminin-coated glass coverslip. Explants were
cultured in 10% FBS-DMEM-F12 (Sigma) in four-well plates for 24 hours. On the
second day, the culture medium was supplemented with nerve growth factor (NGF;
Sigma) at 20 ng/ml and the explants were left in culture for another 24 hours before
fixation in 4% (w/v) paraformaldehyde.
cDNA synthesis, RT-PCR and cloning of rat C6st1
Total RNA was extracted from rat sciatic nerves by the modified acid-phenol-
guanidinium thiocyanate method (Chomczynski and Sacchi, 1987). Oligo-dT-
primed first-strand cDNAs were generated from total RNA using the SuperScript II
kit (Invitrogen, Carlsbad, CA). PCR amplification of cDNAs was performed using
HotstarTaq DNA polymerase (Qiagen, Germany) and degenerate primers
corresponding to conserved sequences of known human, mouse and chick C6ST
genes: sense primer for full-length C6ST-1 (C6ST-F-s), 5-CCATGGAG-
AAAGGACTCRCTTTG-3; antisense primer for full-length C6ST-1, (C6ST-F-as),
5-CTACGTGACCCAGAAGGTGCC-3; sense primer for partial C6ST-1 (C6ST-
P-s), 5-TTCGTKGGSGAGTTCTTCAAC-3; and antisense primer for partial
C6ST-1 (C6ST-P-as), 5-CTCATAGCGCACCARCATGT-3. The latter amplified a
675 bp fragment corresponding to the high homology sequence of C6st1 (427-1101
bp, GenBank AF178689). As a reference, an 843 bp fragment of GAPDH cDNA
was amplified, using primers: 5-CCTTCATTGACCTCAACTACATGGT-3 and
5-TCATTGTTATACCAGGAAATGAGCT-3.
The partial sequence of C6st1 was amplified with PCR initiated at 95°C (15
minutes), followed by 36 cycles at 94°C (50 seconds), 58°C (1 minute), 72°C (1
minute) and terminated at 72°C (7 minutes). The full coding sequence of rat C6ST
was amplified with touch-down PCR, starting with four cycles at 94°C (50 seconds),
60°C (1 minute) and 72°C (1 minute), followed by decreasing annealing temperature
by 3°C for every four cycles and finally 25 cycles at 94°C (50 seconds), 50°C (1
minute) and 72°C (1 minute).
The full-length C6st1 was cloned into pGEM-T-Easy vector (Promega, Madison,
WI) and checked with sequencing (ABI 373A automatic sequencer, Applied
Biosystems). The nucleotide sequence and corresponding amino acid sequence were
analyzed in the ExPASy Proteomics server (Swiss Institute of Bioinformatics).
Sequence alignment with published C6ST-1 sequences was performed with the use
of Clustal W software.
Transient expression of C6st1 in COS-7 cells
A truncated C6st1 cDNA (Bases 142-1425, GenBank accession no. AF178689)
lacking the first 47 amino acids at the N-terminal was amplified from pGEM-C6ST-
1 and inserted into the expression vector pcDNA-HisA (Invitrogen, Carlsbad, CA)
to yield pcDNA-His-C6ST-1. The full coding sequence of C6ST-1 was also
subcloned into pcDNA3.1 to result in pcDNA-C6ST-1.
Both recombinant plasmids were transfected into COS-7 cells using FuGENE 6
Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN) as
recommended by the manufacturer. Briefly, COS-7 cells (5.6106 cells/10 cm dish)
were transfected with the relevant plasmids (4 g). After 65 hours of culture in 10%
FCS-DMEM, the cells were washed and then homogenised in 0.25M sucrose, 20
mM Tris-HCl (pH 7.2), 0.5% Triton X-100. The homogenate was centrifuged
(10,000 g, 15 minutes, 4°C) and the supernatant was kept as the cell extract.
Assay of sulphotransferase activity
Sulphotransferase activity was assayed using chondroitin as acceptor. The assay
mixture contained 50 mM imidazole-HCl (pH 6.8), 1.25 g protamine chloride, 2
mM oDTT, 5 mM MnCl2, 2 mM ATP, 5 g chondroitin (Seikagaku, Japan), 1 M
[35S]3-phosphoadenosine 5-phosphosulphate (PAPS) (about 5105 cpm,
PerkinElmer Life Sciences, Boston, MA), and 10 l of the cell extract in a final
volume of 50 l. The mixture was incubated at 37°C for 2 hours and then mixed
with four volumes of ethanol-potassium chloride (1.3%) to stop the sulphotransferase
reaction. 35S-labelled chondroitin products were separated from [35S]PAPS by
centrifugation followed by gel filtration in a HiTrap desalting column (Amersham
Biosciences, Uppsala, Sweden) and eluted fractions were monitored for radioactivity
with liquid scintillation counting (LS6500; Beckman Coulter, Fullerton, CA).
The remaining 35S-labelled chondroitins in the eluates were precipitated with four
volumes of absolute ethanol (4°C, 16 hours) and centrifuged at 12,000 g (5 minutes,
4°C). Each pellet was redissolved in 20 l Milli-Q water and digested with
chondroitinase ACII (100 mU, Seikagaku, Japan) with or without chondro-6-
sulphatase (50 mU, Seikagaku, Japan) at 37°C for 15 hours. Disaccharide products
were analyzed by chromatography in a Partisil-10 SAX column (Whatman, UK)
(Shum et al., 1999).
Time-lapse video microscopy
DRG explants were cultured on laminin-coated -slides (Ibidi, Munich, Germany)
and maintained in 10% FBS-DMEM-F12 supplemented with NGF (20 ng/ml) at
37°C as described under explant culture. In some cases, cultures were pre-treated
with chondroitinase ABC (10 mU/ml, 37°C, 16 hours) before time-lapse video
capture on day 2 of culture. The enzyme-treated cultures were then paired – one
was incubated with a fresh dose of chondroitinase ABC and the other was incubated
without the enzyme. Phase-contrast images of cell movement in the migration front
were captured with a Spot 4.2 digital camera connected to an Olympus IX71 light
microscope at 3-minute intervals for 180 minutes. The mobility profile of any
selected Schwann cell was determined as the displacement of the cell nucleus per
9-minute step over 180 minutes of video recording.
In situ hybridisation
Sciatic nerves were fixed in 4% (w/v) paraformaldehyde for at least 12 hours before
cryoprotection with 30% (w/v) sucrose in PBS at 4°C for 6-10 hours. Cryosections
(10 m) were thaw-mounted on SuperFrost® glass slides (Menzel-Glaeser,
Germany) and air-dried. Digoxigenin (DIG)-UTP labelled RNA probes (1.4 kb)
were transcribed from pGEM-C6ST-1 with the use of a DIG RNA Labeling Kit
(SP6/T7, Roche Molecular Biochemicals, Mannheim, Germany). In situ
hybridisation (ISH) was performed with minor modifications to standard protocols.
Briefly, cryosections were prewarmed and treated with 20 g/ml Proteinase K at
24°C for 10 minutes. After acetylation with 0.25% (v/v) acetic anhydride in 0.1 M
Journal of Cell Science 119 (5)
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triethanolamine for 10 minutes, sections were washed in PBS and dehydrated.
Hybridisation was carried out with 1 g/ml probe at 55°C, 16 hours. Sections were
then washed twice in 2 SSC, 50% formamide (55°C), followed by more stringent
washes, twice in 0.2 SSC (55°C), once in 0.1 SSC (55°C) and once more at
24°C, each for 20 minutes. In cases of DRG and sciatic nerve explants, post-fixed
tissues were permeabilised with 2 M HCl (24°C, 10 minutes) before proceeding
with acetylation.
To enhance signal detection, the TSATM (Tyramide Signal Amplification) Biotin
System (NENTM Life Science Products, Boston, MA) was applied. Briefly, after
stringent washes, the samples were blocked for 30 minutes before incubation for 1
hour with anti-DIG-peroxidase (1:200; Roche Molecular Biochemicals). Samples
were then incubated in turn with Biotin Tyramide (1:70; 10 minutes), streptavidin-
AP (1:200; 30 minutes). Chromogen was developed by incubation with NBT-BCIP
for 10-20 minutes in a dark, humid chamber. Samples were counterstained in 0.25%
(w/v) methyl green (5 minutes), dehydrated and mounted in aquamount (BDH, UK).
The stained samples were viewed under light microscopy (IX71; Olympus, Japan)
and digital images were imported into CorelDRAW to generate the final figures.
Fluorescence in situ hybridisation in combination with
immunofluorescence
The ISH procedure was the same as described above, except that in the detection
step, streptavidin-AP was replaced by fluorescein-conjugated streptavidin (NENTM
Life Science Products, Boston, MA) at 1:100 dilution. After fluorescence ISH,
samples were incubated for 1 hour with anti-glial fibrillary acidic protein (GFAP)
(1:100; rabbit IgG; Biomedical Technologies, Stoughton, MA), anti-S100 (1:200,
rabbit IgG; DAKO, Denmark) or ED-1 (1:100, mouse IgG; Serotec, Oxford, UK),
followed by incubation for 45 min with TRITC-conjugated anti-rabbit or anti-mouse
IgG (1:100; ICN, USA). Subsequently, they were mounted with Gel/mountTM
(Biomeda, Foster, CA) and examined under a Bio-Rad MRC-1024 confocal system
(Hercules, CA) attached to a Zeiss Axiovert 135M microscope.
Immunocytochemistry prior to in situ hybridisation
Since acid treatment in the ISH procedure interfered with immunostaining with SMI-
31, the latter was performed before ISH. DRG cultures were incubated with SMI-31
(1:1000, mouse IgG; Sternberger Monoclonals, Lutherville, ML) (1 hour, 24°C) after
they had been treated with 1% (v/v) H2O2 to quench endogenous horseradish
peroxidase activity. The DRGs were then incubated with horseradish peroxidase-
linked goat anti-mouse IgG (1:100; Serotec, Oxford, UK) (1 hour, 24°C) and
developed in DAB solution (Pierce, Rockford, IL) for 5 minutes. The tissues were
washed with phosphate-buffered saline and then subjected to ISH as described above.
The stained cultures were viewed by Olympus light microscopy (IX71, Japan).
Double immunofluorescence
Schwann cell cultures were fixed in 4% (w/v) paraformaldehyde, permeabilised with
0.01% (v/v) Triton X-100, and then incubated with anti-S100 (1:100, rabbit IgG;
DAKO, Denmark) and CS56 (1:200, mouse IgM; Sigma) (1 hour, 24°C). This was
followed by incubation with FITC-conjugated goat anti-rabbit IgG (1:100; Sigma)
and TRITC-conjugated goat anti-mouse IgG (1:100; Sigma). Subsequently, they
were mounted with Gel/mountTM (Biomeda).
DRG cultures were treated with chondroitinase ABC or the heat-inactivated
enzyme as control (10 mU/ml, 40 hours, 37°C) before they were incubated live with
monoclonal 3B3 (1:100, mouse IgM, Seikagaku) (45 minutes, 37°C). This was
followed with fixation and permeabilisation, incubation with anti-S100 and then the
mixture of FITC-conjugated goat anti-rabbit IgG and TRITC-conjugated goat anti-
mouse IgG and then mounted with Gel/mountTM as described above.
Viewing and image capture was performed under a Zeiss Axioplan2 microscope
equipped with a Sony CCD camera (DKC-ST5, San Diego, CA) or a Bio-Rad MRC-
1024 confocal system (Hercules, CA) attached to a Zeiss Axiovert 135M
microscope. Image preparation, assembly and analysis were performed in
Photoshop 6.01. In all cases, balance and contrast were adjusted for optimal contrast
and brightness. 
Statistical analysis
Differences between groups were analyzed with the Student’s t-test (InStat v2.04a
program, GraphPad Software) and considered significant at P<0.05. All statistical
tests were two-tailed.
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